政大機構典藏-National Chengchi University Institutional Repository(NCCUR):Item 140.119/79581

English | 正體中文 | 简体中文 | Post-Print筆數 : 27 | Items with full text/Total items : 112871/143842 (78%)
Visitors : 49941980 Online Users : 742

RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.

Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer

政大機構典藏 > 理學院 > 心理學系 > 期刊論文 > Item 140.119/79581

Please use this identifier to cite or link to this item: https://nccur.lib.nccu.edu.tw/handle/140.119/79581

Title:	Perspectives and control of hepatitis B virus infection in Taiwan
Authors:	Lin, Chih-Lin;Kao, Jia-Horng 林志陵
Contributors:	心理系
Keywords:	chronic hepatitis B;HBsAg;HBV DNA;HBV reactivation;hepatocellular carcinoma;risk calculator
Date:	2015-10
Issue Date:	2015-12-03 17:45:12 (UTC+8)
Abstract:	Hepatitis B virus (HBV) infection is endemic in Taiwan. After the implementation of universal hepatitis B vaccination, there was a significant reduction of hepatitis B surface antigen (HBsAg) seropositivity and HBV-related hepatocellular carcinoma (HCC) incidence in children, teenagers, and young adults. However, the incidence of HBV-related HCC in adults remains high. Through several community- and hospital-based cohort studies, the viral factors affecting the prognosis of HBV carriers have been illustrated. Serum HBV DNA level > 2000 IU/mL at study entry starts to increase the risks of cirrhosis and HCC in adult patients with chronic HBV infection. In addition, serum HBsAg level > 1000 IU/mL is associated with a higher risk of HCC in HBeAg-negative patients with low viral load. Virologically, HBV genotype C/D and core promote/pre-S mutations correlate with an increased HCC risk. Recently, a risk calculator has been developed to predict HCC in noncirrhotic patients with external validation. Therapeutically, hospital-based cohort and population-based nationwide studies indicated that interferon and nucleos(t)ide analogue treatments could reduce the incidence of HCC over time. Towards the ultimate goal of HBV eradication, several novel agents aiming at viral and host targets are under development. In addition, the immune therapy may play a key role in HBV cure in the foreseeable future.
Relation:	Journal of the Formosan Medical Association, 114(10), 901-909
Data Type:	article
DOI 連結:	http://dx.doi.org/10.1016/j.jfma.2015.06.003
DOI:	10.1016/j.jfma.2015.06.003
Appears in Collections:	[心理學系] 期刊論文

Files in This Item:

File	Description	Size	Format
901-909.pdf		513Kb	Adobe PDF2	664	View/Open

社群 sharing

著作權政策宣告 Copyright Announcement

1.本網站之數位內容為國立政治大學所收錄之機構典藏，無償提供學術研究與公眾教育等公益性使用，惟仍請適度，合理使用本網站之內容，以尊重著作權人之權益。商業上之利用，則請先取得著作權人之授權。
The digital content of this website is part of National Chengchi University Institutional Repository. It provides free access to academic research and public education for non-commercial use. Please utilize it in a proper and reasonable manner and respect the rights of copyright owners. For commercial use, please obtain authorization from the copyright owner in advance.

2.本網站之製作，已盡力防止侵害著作權人之權益，如仍發現本網站之數位內容有侵害著作權人權益情事者，請權利人通知本網站維護人員(nccur@nccu.edu.tw)，維護人員將立即採取移除該數位著作等補救措施。
NCCU Institutional Repository is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff(nccur@nccu.edu.tw). We will remove the work from the repository and investigate your claim.

Loading...